NCT07775404RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus (EMBOLD-Asia)
Source: ClinicalTrials.gov · Last updated 1 Oct 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adult participants living with obesity or overweight with or without T2DM.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 351 (estimated)
- First submitted
- 17 Aug 2026
- Start date
- 21 Aug 2026
- Primary completion date
- 6 Apr 2028
- Lead sponsor
- AstraZeneca
- Diseases
- Obesity, Type 2 diabetes
- NCT number
- NCT07775404
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 351
- From 21 Aug 2026 to the primary completion date, 6 Apr 2028
- 44 sites in 5 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently receiving, or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema.
- Have had more than one episode of severe hypoglycemia within 180 days prior to the screening visit, or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms.
- History of acute (unless due to previously resolved gallstone pancreatitis and post-cholecystectomy) or chronic pancreatitis.
Other illness
- History/family history (first degree biologic relatives) of medullary thyroid cancer or multiple endocrine neoplasia type 2.
Lab values
- Any of the following medical history, laboratory values, or complications related to diabetes:
- HbA1c ≥ 10% (86 mmol/mol) at the screening visit
Other
- T1DM
Who the study is looking for
- Adult participant aged 18 years or older at the time of informed consent.
- Body mass index (BMI) at screening of:
- 28 kg/m\^2 or higher, or
- 24 kg/m\^2 to less than 28 kg/m\^2 with at least 1 weight-related comorbidity.
- Stable body weight (self-reported or documented) for 90 days prior to the screening visit (± 5% body weight change)
- History of at least 1 self-reported unsuccessful dietary effort to lose body weight.
- Participants with type 2 diabetes mellitus, if enrolled, and have HbA1c from 6.5% to less than 10.0% at screening.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (44)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.